Nuvation Bio Inc. Class A Common Stock vs Viasat — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.93 (market cap $1.74B), while Viasat trades at $73.78 (market cap $9.29B). The key difference: Viasat is far larger — about 5.3× Nuvation Bio Inc. Class A Common Stock's market cap, and Viasat is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Viasat for 10 Days on average.
| NUVB | VSAT | |
|---|---|---|
Market Cap | $1.74B | $9.29B |
Volume | 9,289,619 | 2,084,105 |
Sector | Health | Technology |
52-Week High | $9.54 | $89.81 |
52-Week Low | $3.41 | $30.35 |
Typical Hold Time | 0 Days | 10 Days |
Enterprise Value | $1.33B | $14.48B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →